Role of Class I and Class II histone deacetylases in carcinoma cells using siRNA

Biochemical and Biophysical Research Communications

Volumn 310, Issue 2, 2003, Pages 529-536

  Glaser, Keith B ^a   Li, Junling ^a   Staver, Michael J ^a   Wei, Ru Qi ^a   Albert, Daniel H ^a   Davidsen, Steven K ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Apoptosis; Chromatin remodeling; Gene knockdown; Histone acetylation; Histone deacetylase (HDAC); Histone deacetylase inhibitors; Proliferation; siRNA

Indexed keywords

HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; RNA;

ACETYLATION; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME INHIBITION; GENE CONTROL; HELA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0141570564     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2003.09.043     Document Type: Article

References (39)

1. Davie J., Spencer V. Signal transduction pathways and the modification of chromatin structure. Prog. Nucleic Acids Res. 65:2001;299-340.
2. Wolffe A. Chromatin remodeling: why it is important in cancer. Oncogene. 20:2001;2988-2990.
3. Johnstone R. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nature Rev. 1:2002;287-299.
4. Marks P., Richon V., Rifkind R. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 92:2000;1210-1216.
5. Richon V., Zhou X., Rifkind R., Marks P. Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. Blood Cells Mol. Dis. 27:2001;260-264.
6. He L.-Z., Tolentino T., Grayson P., Zhong S., Warrell R., Rifkind R., Marks P., Richon V., Pandolfi P. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J. Clin. Invest. 108:2001;1321-1330.
7. Gray S., Ekstrom T. The human histone deacetylase family. Exp. Cell Res. 262:2001;75-83.
8. Gao L., Cueto M., Asselbergs F., Atadja P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J. Biol. Chem. 277:2002;25748-25755.
9. Zhou X., Marks P., Rifkind R., Richon V. Cloning and characterization of a histone deacetylase, HDAC9. Proc. Natl. Acad. Sci. (USA). 98:2001;10572-10577.
10. Kao H.-Y., Lee C.-H., Komarov A., Han C., Evans R. Isolation and characterization of mammalian HDAC10, a novel histone deacetylase. J. Biol. Chem. 277:2002;187-193.
11. Ng H., Bird A. Histone deacetylases: silencers for hire. Trends Biochem. Sci. 25:2000;121-126.
12. Saito A., Yamashita T., Mariko Y., Nosaka Y., Tsuchiya K., Ando T., Suzuki T., Tsuruo T., Nakanishi O. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. (USA). 96:1999;4592-4597.
13. Richon V., Emiliani S., Verdin E., Webb Y., Breslow R., Rifkin R., Marks P. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. (USA). 95:1998;3003-3007.
14. Bernstein B., Tong T., Schreiber S. Genomewide studies of histone deacetylase function in yeast. Proc. Natl. Acad. Sci. (USA). 97:2000;13708-13713.
15. Li X., Yoshida M., Beppu T., Lotan R. Modulation of growth and differentiation of human colon carcinoma cells by histone deacetylase inhibitory trichostatins. Int. J. Oncol. 8:1996;431-437.
16. WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. (USA). 97:2000;10014-10019.
17. Butler L., Agus D., Scher H., Higgins B., Rose A., Cordon-Cardo C., Thaler H., Rifkind R., Marks P., Richon V. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 60:2000;5165-5170.
18. Cohen L., Amin S., Marks P., Rifkind R., Desai D., Richon V. Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent suberanilohydroxamic acid (SAHA). Anticancer Res. 19:1999;4999-5006.
19. Glaser K., Staver M., Waring J., Stender J., Ulrich R., Davidsen S. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2:2003;151-163.
20. Furumai R., Komatsu Y., Nishino N., Khochbin S., Yoshida M., Horinouchi S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl. Acad. Sci. (USA). 98:2001;87-92.
21. Yoshida M., Kijima M., Akita M., Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 265:1990;17174-17179.
22. Hoshikawa Y., Kwon H., Yoshida M., Horinouchi S., Beppu T. Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines. Exp. Cell Res. 214:1994;189-197.
23. Munster P., Troso-Sandoval T., Rosen N., Rifkind R., Marks P., Richon V. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res. 61:2001;8492-8497.
24. Marks P., Richon V., Breslow R., Rifkind R. Hybrid polar inducers of transformed cell differentiation/apoptosis. From the cell to the clinic. C. R. Acad. Sci. 322:1999;161-165.
25. Takami Y., Nakayama T. N-terminal region, C-terminal region, nuclear export signal, and deacetylation activity of histone deacetylase-3 are essential for the viability of the DT40 chicken B cell line. J. Biol. Chem. 275:2000;16191-16201.
26. Zhang C., McKinsey T., Chang S., Antos C., Hill J., Olson E. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell. 110:2002;479-488.
27. Liu X., Sun Y., Weinberg R., Lodish H. Ski/Sno and TGF-β signaling. Cytokine Growth Factor Rev. 12:2001;1-8.
28. Akiyoshi S., Inoue H., Hanai J.-i., Kusanagi K., Nemoto N., Miyazono K., Kawabatab M. c-Ski acts as a transcriptional co-repressor in transforming growth factor-β signaling through interaction with Smads. J. Biol. Chem. 1999.
29. Nomura N., Sasamoto S., Ishii S., Date T., Matsui M., Ishizaki R. Isolation of human cDNA clones of ski and the ski-related gene, sno. Nucleic Acids Res. 17:1989;5489-5500.
30. Masuoka Y., Shin-Ya K., Furihata K., Hayakawa Y., Seto H. A novel substance with TGF-β like activity, diheteropeptin, produced by a fungus, Diheterospora sp. J. Antibiot. 50:1997;1058-1060.
31. Masuoka Y., Shin-Ya K., Kim Y.-B., Yoshida M., Nagi K., Suzuki K.-I. Diheteropeptin, a novel substance with TGF-β activity, produced by a fungus Diheterospora chlamydosporia. J. Antibiot. 53:2000;788-792.
32. Masuoka Y., Nagai A., Shin-ya K., Furihata K., Nagai K., Suzuki K.-i., Hayakawa Y., Seto H. Spiruchostatin A and B, novel gene expression-enhancing substances produced by Pseudomonas sp. Tet. Lett. 42:2001;41-44.
33. Sohn T., Su G., Ryu B., Yeo C., Kern S. High-throughput drug screening of the DPC4 tumor-suppressor pathway in human pancreatic cancer cells. Ann. Surgery. 233:2001;696-703.
34. Su G., Sohn T., Rhyu B., Kern S. A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res. 60:2000;3137-3142.
35. Glaser K., Li J., Aakre M., Morgan D., Sheppard G., Stewart K., Pollock J., Lee P., O'Connor C., Anderson S., Mussatto D., Wegner C., Moses H. Transforming growth factor β mimetics: discovery of 7-[4-(4-cyanophenyl)phenoxy]-heptanohydroxamic acid, a biaryl hydroxamate inhibitor of histone deacetylase. Mol. Cancer Ther. 1:2002;759-768.
36. Kao H., Downes M., Ordentlich P., Evans R. Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression. Gene Dev. 14:2000;55-66.
37. Li J., Wang J., Wang J., Nawaz Z., Liu J., Qin J., Wong J. Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. EMBO J. 19:2000;4342-4350.
38. Fischle W., Dequiedt F., Hendzel M., Guenther M., Lazar M., Voelter W., Verdin E. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol. Cell. 9:2002;45-57.
39. Guenther M., Barak O., Lazar M. The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3. Mol. Cell. Biol. 21:2001;6091-6101.